References
- Trausch B., Oertel R., Richter K., Gramatte T. Disposition and bioavailability of the beta 1-adrenoceptor antagonist talinolol in man. Biopharm. Drug Dispos. 1995; 16: 403–414
- Wetterich U., Spahn-Langguth H., Mutschler E., Terhaag B., Rosch W., Langguth P. Evidence for intestinal secretion as an additional clearance pathway of talinolol enantiomers: concentration- and dose-dependent absorption in vitro and in vivo. Pharm. Res. 1996; 13: 514–522
- Terhaag B., Sahre H., Lange U., Richter K., Feller K. Zum einfluß der nahrung auf die absorption von talinolol (cordanum) an gesunden probanden. Z. Klin. Med. 1991; 46: 1021–1023
- Giessmann T., Zschiesche M., Modess C., Tschuschke A., Hartmann V., Weitschies W., Siegmund W. Is the double peak phenomenon of talinolol caused by lymphatic transport?. Pharmacol. Toxicol. 2001; 89(Supplement I)73, (Abstract)
- Oertel R., Richter K. Die metaboliten des beta-rezeptorenblockers talinolol–zusammenhang zwischen struktur, polarität und ausgeschiedener menge. Pharmazie 1995; 50: 637–638
- Oertel R., Richter K., Trausch B., Berndt A., Gramatte T., Kirch W. Elucidation of the structure of talinolol metabolites in man. Determination of talinolol and hydroxylated talinolol metabolites in urine and analysis of talinolol in serum. J. Chromatogr. B. Biomed. Appl. 1994; 660: 353–363
- Preiss R. P-Glycoprotein and related transporters. Int. J. Clin. Pharmacol. Ther. 1998; 36: 3–8
- Wagner D., Spahn-Langguth H., Hanafy A., Koggel A., Langguth P. Intestinal drug efflux: formulation and food effects. Adv. Drug Deliv. Rev. 2001; 50(Suppl 1)S13–S31
- Suzuki H., Sugiyama Y. Role of metabolic enzymes and efflux transporters in the absorption of drugs from the small intestine. Eur. J. Pharm. Sci. 2000; 12: 3–12
- Gramatte T., Oertel R., Terhaag B., Kirch W. Direct demonstration of small intestinal secretion and site-dependent absorption of the beta-blocker talinolol in humans. Clin. Pharmacol. Ther. 1996; 59: 541–549
- Hunter J., Hirst B.H., Simmons N.L. Drug absorption limited by P-glycoprotein-mediated secretory drug transport in human intestinal epithelial Caco-2 cell layers. Pharm. Res. 1993; 10: 743–749
- Wetterich U., Spahn-Langguth H., Mutschler E., Terhaag B., Rosch W., Langguth P. Evidence for intestinal secretion as an additional clearance pathway of talinolol enantiomers: concentration- and dose-dependent absorption in vitro and in vivo. Pharm. Res. 1996; 13: 514–522
- Wagner D., Spahn-Langguth H., Hanafy A., Koggel A., Langguth P. Intestinal drug efflux: formulation and food effects. Adv. Drug Deliv. Rev. 2001; 50(Suppl 1)S13–S31
- Ungell A.L., Nylander S., Bergstrand S., Sjoberg A., Lennernas H. Membrane transport of drugs in different regions of the intestinal tract of the rat. J. Pharm. Sci. 1998; 87: 360–366
- Fagerholm U., Lindahl A., Lennernas H. Regional intestinal permeability in rats of compounds with different physicochemical properties and transport mechanisms. J. Pharm. Pharmacol. 1997; 49: 687–690
- Dressman J.B., Amidon G.L., Reppas C., Shah V.P. Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms. Pharm. Res. 1998; 15: 11–22
- Avdeef A. Pharmacokinetic optimization in drug research: biological, physicochemical, and computational strategies. High-Throughput Measurements of Solubility Profiles, B. Testa, H. van de Waterbeemd, G. Folkers, R. Guy. Wiley-VCH. 2001; 305–326
- Dressman J.B., Amidon G.L., Reppas C., Shah V.P. Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms. Pharm. Res. 1998; 15: 11–22
- Galia E., Nicolaides E., Horter D., Lobenberg R., Reppas C., Dressman J.B. Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs. Pharm. Res. 1998; 15: 698–705
- Spahn-Langguth H., Baktir G., Radschuweit A., Okyar A., Terhaag B., Ader P., Hanafy A., Langguth P. P-glycoprotein transporters and the gastrointestinal tract: evaluation of the potential in vivo relevance of in vitro data employing talinolol as model compound. Int. J. Clin. Pharmacol. Ther. 1998; 36: 16–24
- Lennernas H., Regardh C.G. Evidence for an interaction between the beta-blocker pafenolol and bile salts in the intestinal lumen of the rat leading to dose-dependent oral absorption and double peaks in the plasma concentration-time profile. Pharm. Res. 1993; 10: 879–883